Basic Research
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2007; 13(21): 3009-3015
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.3009
Table 1 Summary of clinicopathological data (n = 259)
CharacteristicsCases (%)
Gender
Male146 (56.4)
Female113 (43.6)
Age (yr)
Range18-80
Median56
Tumor location
> 10 cm162 (23.9)
7-10 cm1115 (44.4)
5-7 cm182 (31.7)
Mean Max diameter (cm)4.68
Pathology
Adenocarcinoma236 (91.1)
Mucinous aden318 (6.9)
Signet ring ca35 (2)
T stage
T118 (7.0)
T283 (32.0)
T385 (32.8)
T473 (28.2)
N stage
N0147 (56.8)
N162 (23.9)
N250 (19.3)
TNM stage (AJCC/UICC)
I80 (30.9)
II67 (25.9)
III112 (43.2)
Lymphovascular invasion
Yes33 (12.7)
No226 (87.3)
Neural invasion
Yes21 (8.1)
No238 (91.9)
Pre-operative CEA2
Positive48 (18.5)
Negative211 (81.5)
Adjuvant therapy
S167 (64.5)
S + C92 (35.5)
Table 2 Distribution of stage II or III patients with or without adjuvant chemotherapy
Adjuvant chemotherapy(n = 179)
P
No
Yes
Cases%Cases%
N stagingN011468.23335.9< 0.05
N13319.82931.5
N220123032.4
T stagingT1-29053.91112< 0.05
T33822.74751
T43923.43437
DifferentiationHigh-Medium14586.87783.7> 0.05
Low2213.21516.3
Lymphovascular invasionNone1911.41415.6> 0.05
Yes14888.67884.4
Neural invasionNone148.477.6> 0.05
Yes15491.68592.4
Table 3 Association between IHC and clinicopathological data
CharacteristicsP53 (n)
P21 (n)
PCNA (n)
CD44 (n)
+-P+-P+-P+-P
Tumor locationHigh2933NS539NS3626NS3230NS
Median5362932270456352
Low3646631953293448
PathologyAdeno.109127NS19145< 0.0514492NS117119NS
Muci810162135117
Signet14232314
TNM stageI3446NS5921NS4733NS3743NS
II303758942253334
III5458922070425953
Invasion depthT1-24655NS74270.0526338NS4655NS
T33649721355304342
T43637631041324033
Lymphnode meta.N06483NS11730NS8958NS7077NS
N1-25458922070425953
Lymph-vascular invasion+1716NS258NS2112NS1914NS
-1011251844213888110116
Neural invasion+1110NS183NS156NS1110NS
-107131191474494118120
Preoperative CEA+1830NS417NS3018NS109102NS
-10011116842129822028
Table 4 Variables association with overall survival, DFS, recurrence and metastasis
nSurvival
DFS
Local recurrence
Metastasis
%P%P%P%P
Gender
Male14685.6NS78.1< 0.055.5NS16.4NS
Female11389.487.62.79.7
Tumor locationNSNSNS
High6288.785.53.212.9
Medium11587.883.56.110.4NS
Low8285.480.52.418.3
Pathology< 0.05< 0.05< 0.05
Adenocarcinoma23687.783.93.813.1
Mucinous cancer1894.483.35.611.1NS
Signet ring cancer540402040
Differentiation
High-medium22287.4NS82.9NS4.1NS13.1NS
Low3786.578.45.416.2
TNM staging< 0.05< 0.05< 0.05
I809592.51.36.3
II6792.589.61.59.0< 0.05
III11278.670.3821.4
Invasion depth< 0.05<0.05NS
T1-210195.091.126.9
T38583.578.84.716.5< 0.05
T47380.875.36.819.2
N staging< 0.05< 0.05< 0.05
N014793.991.21.47.5< 0.05
N1-211278.672.38.021.4
Lymphvascular invasionNSNSNS
+3381.878.86.115.2
-22688.183.6413.3NS
Neural invasionNSNS
+2185.7NS85.74.814.3
-23887.482.84.213.4NS
Preoperative CEA0.06< 0.05NS
+4820.831.36.325
-21110.914.73.810.9< 0.05
P53NSNS
+11884.480.96.40.0613.5NS
-14190.785.61.713.6
P21NSNSNS
+20987.681.84.313.9NS
-5086844.012.0
PCNANSNSNS12.6
+15989.384.33.115.0NS
-10084.081.06.0
CD44< 0.05< 0.05NS
+12982.976.76.217.10.97
-13091.587.82.310.0